Funding & VC

TestDynamics Raises $9 Million Series A for Medical Imaging AI Evaluation

TestDynamics raised $9 million led by Healthier Capital to expand Satori, a platform that tests imaging AI on hospitals' own studies and monitors performance after deployment.

By Olivia Hart

4 min read

TestDynamics Secures $9 Million With Series A Backing for Medical Imaging AI Evaluation
TestDynamics Secures $9 Million With Series A Backing for Medical Imaging AI EvaluationAI-generated

What's News

  • TestDynamics raised $9 million in a Series A led by Healthier Capital, with Cedars-Sinai Technology Ventures participating.
  • Satori is in clinical use at several of the ten highest-ranked U.S. medical centers, though none are named and no valuation is disclosed.
  • TestDynamics participated in the Cedars-Sinai Accelerator's 2023 program.
  • Satori Edge de-identifies studies inside the hospital network; vendor agreements bar retaining patient data or using it for training.
  • A 2024 Nature Medicine comment argued for stronger evidence standards for authorized AI health tools.

TestDynamics has raised $9 million in a Series A led by Healthier Capital, with strategic participation from Cedars-Sinai Technology Ventures, to expand Satori, a vendor-neutral platform that evaluates medical imaging AI algorithms and pipes their findings into radiologists' existing workflows.

The Austin-based company is betting on a structural gap in hospital AI adoption. Choosing an algorithm is only the start; health systems must also verify how it performs on their own patients, integrate it with clinical software, and check that it keeps delivering useful results after deployment. Each of those steps is work the algorithm vendors themselves have little incentive to do rigorously.

TestDynamics says Satori is already in clinical use at several of the ten highest-ranked U.S. medical centers. It plans to grow its clinical validation team, deploy across more health systems, and extend evaluation and orchestration into additional imaging subspecialties. The announcement names none of those medical centers and discloses no valuation — claims of adoption, in other words, rest on the company's word alone.

Why an outside evaluator?

Medical imaging AI is narrow by design. One tool flags suspected bleeding on a head CT; another measures structures on an MRI or detects possible fractures on an X-ray. Buy several, and radiologists end up reconciling separate interfaces, findings, and vendor-specific performance claims.

Satori sits above those tools rather than competing as another diagnostic algorithm. TestDynamics calls the approach Amalgamated Intelligence: it evaluates outputs from multiple systems and organizes the results into a prioritized clinical view, benchmarking algorithms against reference findings — so-called ground truth — and against rival products.

"Evaluation must come from outside the model," said founder and CEO Lior Eshel in the announcement. His argument is that hospitals need an evaluator whose role is separate from the companies selling the algorithms.

The practical mechanism: candidate tools are tested on the provider's own de-identified imaging studies before clinicians and leadership choose them. Those results set a local baseline for later monitoring. A model's performance elsewhere is evidence, but only a local test shows whether that evidence carries over to a hospital's actual imaging workload.

How the pipes work

Satori Edge, the integration component, runs inside the hospital network. According to TestDynamics' technical overview for IT teams, it receives studies from PACS — the picture archiving and communication system that stores and retrieves medical images — and from DICOM routers, which move images under the industry's standard exchange format.

Edge de-identifies and encrypts studies before they leave the network, routes them only to AI vendors the hospital has enabled, and reconnects returned results with the correct patient on site. The company says the service uses outbound connections and that vendor agreements prohibit retaining patient data or using it for training. That is the vendor's description; the announcement offers no third-party audit of it.

The architecture also consolidates contracting. TestDynamics holds the agreements and business associate agreements with underlying AI vendors, covering responsibilities for protected health information while the technical layer handles movement of studies and results.

One view, but radiologists still approve

"One result" might suggest AI answers blended into a new diagnosis. Satori View documentation describes something more limited: individual results appear as the originating algorithm produced them, organized into a consistent view at the point of reading.

Clinical sections choose which findings appear and in what order. Radiologists approve what enters the imaging viewer or draft report. Priority flags from cleared triage tools can reach worklists, and follow-up tracking keeps incidental findings visible until addressed. That distinction matters for accountability — a radiologist needs to know which tool produced a finding, and to be able to reject it.

What happens after go-live?

Satori Governance extends evaluation into operations. TestDynamics says it tracks performance against each hospital's baseline, monitors usage, compares AI findings with final reports, and logs radiologists' agreements, overrides, and disagreements. Leadership uses that record to decide whether to keep, replace, or expand a tool.

The target is drift: performance changes triggered by scanner upgrades, new imaging protocols, different patient populations, or updated model versions. But agreement with a final report is not the same as independently adjudicated ground truth, and reviewing disagreements remains labor-intensive — which is why the funding emphasizes expanding the validation team.

The demand for external evaluation extends beyond imaging. A 2024 Nature Medicine comment on clinical validation argued for stronger evidence standards for authorized AI health tools, part of a wider push to assess systems against evidence outside their developers' own claims.

Healthier Capital's bet is infrastructure: hospitals will need to swap AI vendors without rebuilding clinical systems around each replacement. Cedars-Sinai Technology Ventures adds a healthcare commercialization investor; TestDynamics participated in the Cedars-Sinai Accelerator's 2023 program. Whether the $9 million buys hospitals clearer evidence about their tools — and a more usable flow of findings for radiologists — will decide if the evaluation layer becomes standard infrastructure or another middleware layer with unproven claims.

Source: unite.ai

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,205 articles

Related articles

« Previous articleNext article »